Results 81 to 90 of about 114,702 (262)
Single cell imaging of Bruton's Tyrosine Kinase using an irreversible inhibitor [PDF]
, 2014 A number of Bruton's tyrosine kinase (BTK) inhibitors are currently in development, yet it has been difficult to visualize BTK expression and pharmacological inhibition in vivo in real time.
Kim, Eunha +4 more
core +1 more source
Blood, 2018 Background: The Bruton tyrosine kinase (BTK) inhibitor zanubrutinib,has demonstrated greater selectivity for BTK versus other TEC- and EGFR-family kinases in biochemical assays and favorable pharmacokinetic/pharmacodynamic properties in preclinical ...
Yuqin Song +20 more
semanticscholar +1 more source
Journal of Intelligent Medicine, EarlyView.Abstract Kinase inhibitors are essential in targeted cancer therapy, yet resistance often emerges through secondary mutations, activation of compensatory signaling pathways, or drug‐efflux mechanisms. Artificial intelligence (AI) provides a workflow‐based strategy rather than a list of unrelated tools for predicting and addressing kinase‐inhibitor ...
Faris Hassan +3 more
wiley +1 more source
Ibrutinib: the first Bruton's tyrosine kinase inhibitor [PDF]
Prescriber, 2018 Bruton's tyrosine kinase (BTK) is emerging as a promising target in the treatment of B‐cell malignancies. This article discusses the properties of the first licensed BTK inhibitor, ibrutinib (Imbruvica) and its place in the management of mantle cell lymphoma, chronic lymphocytic leukaemia and Waldenström's macroglobulinaemia.
openaire +1 more source
Bruton’s Tyrosine Kinase (BTK)-Inhibitors in Cancer Therapeutics
Global Journal of Oncologists, 2021 While continuous global efforts are directed towards finding a conclusive medication for cancer treatment, any gold standard drug product or process is yet to be achieved. Although, many promising compounds were identified over the years to fight cancer progression, most of them still remain restricted within clinical trial phases.
Amarendranath Choudhury +1 more
openaire +1 more source
Cells, 2023 In chronic lymphocytic leukemia (CLL), an elevated glycosyltransferase UGT2B17 expression (UGT2B17HI) identifies a subgroup of patients with shorter survival and poor drug response. We uncovered a mechanism, possibly independent of its enzymatic function,
Antoine Wagner +14 more
doaj +1 more source
Frontiers in Pharmacology, 2021 Ibrutinib is an orally bioavailable, irreversible selective Bruton’s tyrosine kinase inhibitor that has demonstrated impressive therapeutic effects in patients with B cell malignancies.
Kun Wang, Qiushi Xu, Hanbing Zhong
semanticscholar +1 more source
New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa
JEADV Clinical Practice, EarlyView.ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender +2 more
wiley +1 more source
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT Ibrutinib resistance remains a major obstacle in the treatment of diffuse large B‐cell lymphoma (DLBCL). Fat mass and obesity‐associated protein (FTO) has been implicated in drug resistance through its regulation of N6‐methyladenosine (m6A) modifications; however, whether FTO mediates ibrutinib resistance in DLBCL remains unclear.
Ting‐Ting Lu +5 more
wiley +1 more source
JIIS: Jurnal Ilmiah Ibnu Sina, 2019 ABSTRAK Bruton Tirosin kinase (BTK) memainkan peran penting dalam banyak jalur pensinyalan seluler sehingga menjadikannya target potensial dalam mengobati penyakit autoimun dan kanker.
Fauzan Zein Muttaqin +4 more
doaj +3 more sources